ICON Public Limited Company (ICLR) Forms $121.82 Double Top; Last Week Nxstage Medical, Inc. (NXTM) Coverage

May 9, 2018 - By Russell Anderson

Nxstage Medical, Inc. (NASDAQ:NXTM) Logo

ICON Public Limited Company (ICLR) formed double top with $130.35 target or 7.00% above today’s $121.82 share price. ICON Public Limited Company (ICLR) has $6.59B valuation. The stock increased 0.49% or $0.6 during the last trading session, reaching $121.82. About 186,464 shares traded. ICON Public Limited Company (NASDAQ:ICLR) has risen 52.69% since May 9, 2017 and is uptrending. It has outperformed by 41.14% the S&P500.

Among 9 analysts covering NxStage Medical (NASDAQ:NXTM), 2 have Buy rating, 1 Sell and 6 Hold. Therefore 22% are positive. NxStage Medical had 19 analyst reports since November 4, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Monday, October 16 by Canaccord Genuity. The firm has “Hold” rating by Craig Hallum given on Thursday, April 5. Leerink Swann downgraded Nxstage Medical, Inc. (NASDAQ:NXTM) on Tuesday, August 22 to “Market Perform” rating. Jefferies maintained the shares of NXTM in report on Tuesday, October 10 with “Hold” rating. The rating was initiated by BTIG Research with “Buy” on Friday, December 18. As per Tuesday, June 28, the company rating was upgraded by Northland Capital. As per Monday, August 7, the company rating was downgraded by Craig Hallum. As per Monday, September 11, the company rating was maintained by Canaccord Genuity. The stock of Nxstage Medical, Inc. (NASDAQ:NXTM) has “Neutral” rating given on Friday, August 11 by BTIG Research. Sterne Agee CRT initiated the shares of NXTM in report on Friday, December 11 with “Buy” rating. See Nxstage Medical, Inc. (NASDAQ:NXTM) latest ratings:

05/04/2018 Broker: Craig Hallum Rating: Hold New Target: $30.0000 Maintain

More news for Nxstage Medical, Inc. (NASDAQ:NXTM) were recently published by: Globenewswire.com, which released: “Consolidated Research: 2018 Summary Expectations for The Mosaic, Newmont Mining, National Oilwell Varco …” on May 08, 2018. Prnewswire.com‘s article titled: “Medisystems Announces US Release of MasterGuardĀ® Plus” and published on April 13, 2018 is yet another important article.

The stock increased 0.69% or $0.18 during the last trading session, reaching $26.43. About 186,459 shares traded. Nxstage Medical, Inc. (NASDAQ:NXTM) has declined 9.81% since May 9, 2017 and is downtrending. It has underperformed by 21.36% the S&P500.

Since January 16, 2018, it had 0 buys, and 2 sales for $172,760 activity. 3,500 shares valued at $85,680 were sold by Swan Winifred L on Tuesday, February 20.

Investors sentiment increased to 1.25 in 2017 Q4. Its up 0.34, from 0.91 in 2017Q3. It improved, as 22 investors sold Nxstage Medical, Inc. shares while 41 reduced holdings. 31 funds opened positions while 48 raised stakes. 47.78 million shares or 7.32% less from 51.56 million shares in 2017Q3 were reported. Ameriprise Fin Inc has 0% invested in Nxstage Medical, Inc. (NASDAQ:NXTM). Invesco Ltd, a Georgia-based fund reported 1.72M shares. Neuberger Berman Gp Ltd Com owns 15,277 shares or 0% of their US portfolio. Moreover, Falcon Edge Cap Limited Partnership has 4.39% invested in Nxstage Medical, Inc. (NASDAQ:NXTM). Broadview Advsr Ltd Company has 62,256 shares for 0.21% of their portfolio. Dafna Mngmt Lc has invested 2.82% in Nxstage Medical, Inc. (NASDAQ:NXTM). 40,250 were accumulated by Bluecrest Cap Management. Northern Tru holds 0.01% or 859,769 shares. Deutsche Retail Bank Ag owns 1.93M shares for 0.03% of their portfolio. Pnc Fin Group owns 52 shares or 0% of their US portfolio. Moreover, Alpine Associates Mngmt has 3.5% invested in Nxstage Medical, Inc. (NASDAQ:NXTM). Great West Life Assurance Can holds 0% of its portfolio in Nxstage Medical, Inc. (NASDAQ:NXTM) for 8,228 shares. Moreover, Cqs Cayman L P has 0.03% invested in Nxstage Medical, Inc. (NASDAQ:NXTM). Legal And General Plc has 31,587 shares. Swiss Comml Bank accumulated 0% or 122,700 shares.

NxStage Medical, Inc., a medical technology company, develops, makes, and markets services and products for patients suffering from chronic or acute kidney failure. The company has market cap of $1.76 billion. The Company’s primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting. It currently has negative earnings. The firm operates through three divisions: System One, In-Center, and Services.

Among 12 analysts covering Icon plc (NASDAQ:ICLR), 7 have Buy rating, 1 Sell and 4 Hold. Therefore 58% are positive. Icon plc has $145.0 highest and $77 lowest target. $120.55’s average target is -1.04% below currents $121.82 stock price. Icon plc had 40 analyst reports since July 29, 2015 according to SRatingsIntel. SunTrust upgraded ICON Public Limited Company (NASDAQ:ICLR) on Monday, July 31 to “Buy” rating. The company was maintained on Monday, November 13 by KeyBanc Capital Markets. Jefferies downgraded the shares of ICLR in report on Friday, June 3 to “Hold” rating. Jefferies maintained it with “Buy” rating and $122.0 target in Monday, September 11 report. The stock of ICON Public Limited Company (NASDAQ:ICLR) earned “Buy” rating by Credit Suisse on Monday, October 16. Jefferies maintained the shares of ICLR in report on Thursday, February 15 with “Buy” rating. The rating was maintained by Robert W. Baird with “Buy” on Thursday, February 15. The rating was downgraded by Suntrust Robinson on Friday, December 16 to “Hold”. Avondale initiated the shares of ICLR in report on Wednesday, October 21 with “Market Perform” rating. Robert W. Baird maintained ICON Public Limited Company (NASDAQ:ICLR) rating on Thursday, August 31. Robert W. Baird has “Buy” rating and $120.0 target.

Nxstage Medical, Inc. (NASDAQ:NXTM) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>